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Background: Patients with type 2 diabetes (T2D) are at elevated risk for cardiovascular disease (CVD) events and
mortality. Recent studies have assessed the impact of genetic variants affecting high-density lipoprotein cholesterol
(HDL) concentrations on CVD risk in the general population. This study examined the utility of HDL-associated
single nucleotide polymorphisms (SNPs) for CVD risk prediction in European Americans with T2D enrolled in the
Diabetes Heart Study (DHS).
Methods: Genetic risk scores (GRS) of HDL-associated SNPs were constructed and evaluated for potential
associations with mortality and with coronary artery calcified atherosclerotic plaque (CAC), a measure of subclinical
CVD strongly associated with CVD events and mortality. Two sets of SNPs were used to construct GRS; while all
SNPs were selected primarily for their impacts on HDL, one set of SNPs had pleiotropic effects on other lipid
parameters, while the other set lacked effects on low-density lipoprotein cholesterol (LDL) or triglyceride
concentrations.
Results: The GRS were specifically associated with HDL concentrations (4.90 × 10-7 < p < 0.02) in models adjusted
for age, sex, and body mass index (BMI), but were not associated with LDL or triglycerides. Cox proportional
hazards regression analysis suggested the HDL-associated GRS had no impact on risk of CVD-mortality (0.48 <
p < 0.99) in models adjusted for other known CVD risk factors. However, associations between several of the GRS
and CAC were observed (3.85 × 10-4 < p < 0.03) in models adjusted for other known CVD risk factors.
Conclusions: The GRS analyzed in this study provide a tool for assessment of HDL-associated SNPs and their
impact on CVD risk in T2D. The observed associations between several of the GRS and CAC suggest a potential role
for HDL-associated SNPs on subclinical CVD risk in patients with T2D.
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Patients with T2D have significantly increased risk for
CVD, with mortality rates from heart disease at least two-
fold higher than in adults without diabetes [1]. In addition,
patients with T2D have higher rates of dyslipidemia, an
important CVD risk factor. In particular, individuals with
T2D tend to have increased triglyceride concentrations
and decreased HDL cholesterol concentrations [2]. An
inverse relationship between HDL concentrations and
CVD-mortality has long been observed [3]; however, it
is not clear whether HDL is a significant contributing
factor in development of CVD and whether interven-
tions to specifically alter HDL concentrations markedly
impact CVD risk.
Voight et al. [4] used Mendelian randomization to as-
sess the impact of HDL concentrations on myocardial
infarction (MI) risk in over 12,000 MI cases and over
40,000 controls. Neither a coding variant in LIPG nor a
genetic risk score (GRS) derived from 14 common SNPs,
both of which were robustly associated with HDL and
not with other lipid parameters, was associated with MI.
A one standard deviation increase in HDL cholesterol
due to GRS was not associated with a significant change
in MI risk, though epidemiological data suggested a
change in HDL concentration of this magnitude would
be associated with an approximate 38% reduction in risk
for MI. These data do not support a major role for
HDL-associated SNPs in MI.
Given that CVD accounts for more than 65% of all-
cause mortality in individuals with T2D, determining the
effects of HDL concentrations on CVD in this high risk
group is of particular interest [1], as low HDL concen-
trations have been epidemiologically associated with
CVD risk in T2D [5]. Previous large meta-analyses have
not specifically analyzed the effect of HDL associated
GRS in clinically relevant, community-based cohorts of
patients at high risk for CVD, such as patients with T2D.
In the current study we constructed GRS containing
SNPs associated solely with HDL, SNPs associated with
HDL which have apparent pleiotropic effects on other
lipid parameters, and both sets of SNPs for analysis in
combined scores. We analyzed these GRS for associa-
tions with mortality and a measure of subclinical CVD
burden, coronary artery calcified atherosclerotic plaque
(CAC) [6-8], in a cohort of patients with T2D from the
Diabetes Heart Study (DHS).
Methods
Study design and sample
DHS participants were recruited from outpatient in-
ternal medicine and endocrinology clinics and from the
community from 1998 through 2005 in western North
Carolina. Siblings concordant for T2D without advanced
renal insufficiency were recruited, with additional non-diabetic siblings enrolled whenever possible. Recruitment
was based upon family structure, and there were no inclu-
sions/exclusions based on evidence of prevalent CVD at
the time of recruitment. Ascertainment and recruitment
have been described in detail previously [9-12]. T2D was
defined as diabetes developing after the age of 35 years
treated with insulin and/or oral agents, in the absence of
historical evidence of ketoacidosis. Diabetes diagnosis was
confirmed by measurement of fasting glucose and glycated
hemoglobin (HbA1C) at the exam visit. Analyses com-
pleted for the current investigation included 983 self-
described European American individuals with T2D from
466 DHS families.
Study protocols were approved by the Institutional Re-
view Board at Wake Forest School of Medicine, and all
participants provided written informed consent. Partici-
pant examinations were conducted in the General Clin-
ical Research Center of the Wake Forest Baptist Medical
Center. Examinations included interviews for medical
history and health behaviors, anthropometric measures,
resting blood pressure, electrocardiography, fasting blood
sampling for laboratory analyses, and spot urine collec-
tion. Individuals were considered hypertensive if they were
prescribed anti-hypertensive medication or had blood
pressure measurements exceeding 140 mmHg (systolic) or
90 mmHg (diastolic). Standard laboratory analyses in-
cluded fasting glucose, HbA1C, total cholesterol, HDL, and
triglycerides. Low-density lipoprotein cholesterol (LDL)
concentration was calculated using the Friedewald
equation, and LDL concentrations were considered valid
for subjects whose triglycerides were less than 796 mg/
dL. CAC was measured using fast-gated helical com-
puted tomography (CT) scanners, and calcium scores
were calculated as previously described and reported as
an Agatston score [13,14].
Vital status was determined for all subjects from the
National Social Security Death Index maintained by the
United States Social Security Administration. For partici-
pants confirmed as deceased, length of follow-up was
determined from the date of initial study visit to date of
death. For all other participants, the length of follow-up
was determined from the date of the initial study visit to
the end of 2011. For deceased participants, copies of death
certificates were obtained from relevant county Vital Re-
cords Offices to determine cause of death. Cause of death
was categorized based on information contained in death
certificates as CVD-mortality (MI, congestive heart failure,
cardiac arrhythmia, sudden cardiac death, peripheral
vascular disease, and stroke) or either cancer, infection,
end-stage renal disease, accidental, or other (including ob-
structive pulmonary disease, pulmonary fibrosis, liver fail-
ure and Alzheimer’s dementia). Association with mortality
was assessed for both CVD-mortality and all-cause mor-
tality, i.e. death from any cause.
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Total genomic DNA was purified from whole blood sam-
ples using the PUREGENE DNA isolation kit (Gentra Inc.,
Minneapolis, MN). DNA concentration was quantified
using standardized fluorometric readings on a Hoefer
DyNA Quant 200 fluorometer (Hoefer Pharmacia Biotech
Inc., San Francisco, CA). Genotype data for specific SNPs
was derived from: (i) the MassARRAY SNP Genotyping
System (Sequenom Inc., San Diego, CA) (n = 4 SNPs),
(ii) a genome wide association study (GWAS) using the
Affymetrix® Genome-Wide Human SNP Array 5.0
(Affymetrix® Inc., Santa Clara, CA) (n = 2 SNPs), (iii)
Illumina® HumanExome BeadChips (Illumina® Inc., San
Diego, CA) (n = 18 SNPs), and (iv) GWAS imputed data
(n = 4 SNPs).
Genotyping using the MassARRAY SNP Genotyping
System was completed as described previously [15].
Primers for PCR amplification and extension reactions
were designed using the MassARRAY Assay Design
Software (Sequenom). Samples were diluted to a final
concentration of 5 ng/μl, and single-base extension re-
action products were separated and scored using a
matrix-assisted laser desorption ionization/time of flight
mass spectrometer. To evaluate genotyping accuracy, 39
quality control samples were included as blind dupli-
cates. The concordance rate for these blind duplicates
was 100%.
For the DHS GWAS data, genotype calling was com-
pleted using the BRLLM-P algorithm in Genotyping
Console v4.0 (Affymetrix). Samples failing to meet an
intensity quality control threshold (n = 4) were not in-
cluded for genotype calling and those failing to meet a
minimum acceptable call rate of 95% (n = 3) were ex-
cluded from further analyses. An additional 39 samples
were included as blind duplicates within the genotyping
set to serve as quality controls; the concordance rate for
these blind duplicates was 99.0 ± 0.72% (mean ± standard
deviation (SD)).
For the DHS Exome Chip data, genotype calling was
completed using Genome Studio Software v1.9.4 (Illumina).
Samples failing to meet a minimum acceptable call rate of
98% (n = 3) were excluded from further analyses. An add-
itional 58 samples were included as blind duplicates within
the genotyping set to serve as quality controls; the con-
cordance rate for blind duplicates was 99.9 ± 0.0001%
(mean ± SD). Additional quality control of GWAS and
Exome Chip data sets was completed to exclude sam-
ples with poor quality genotype calls, gender errors, or
unclear/unexpected sibling relationships.
For SNPs where direct genotyping data was not avail-
able, genotype data was obtained from GWAS imputed
data. Imputation of 1,000 Genomes Project SNPs was
completed using the program IMPUTE2 and the Phase I
v2, cosmopolitan (integrated) reference panel, build 37[16,17]. SNPs that were used for imputation were required
to have low missingness and show no significant departure
from Hardy-Weinberg expectations (p > 1 × 10-4). To
maximize the quality of imputation, the samples were
not pre-phased. Only imputed SNPs with a confi-
dence score > 0.90 and information score > 0.50 were
used. A total of ~4.5 million SNPs passed imputation
quality control.
For all SNPs used to derive the GRS, the minimum ac-
ceptable call rate was 95%; the average SNP call rate was
99.4% ± 1.2% (mean ± SD), and the average sample call
rate was 99.4% ± 1.4%. Allele and genotype frequencies
were calculated from unrelated individuals and tested
for departures from Hardy-Weinberg equilibrium. No
SNPs showed significant departure from Hardy-Weinberg
equilibrium (p > 0.05). One SNP (rs386000) included by
Voight et al. [4] in their HDL GRS failed genotyping and
was not included in the current analysis.
GRS calculation
Both unweighted GRS and GRS weighted by SNP effect
size were derived for two sets of SNPs previously
reported to be associated with HDL [4]. One set of 14
SNPs had documented effects on HDL concentrations
only and were used by Voight et al. [4] for construction
of a GRS. We created GRS from 13 of these SNPS with
good quality genotyping data (rs386000 excluded) (Score
1; 1a = unweighted, 1b = weighted).
In addition, Voight et al. [4] also reported an add-
itional set of 15 SNPs, including a coding variant in
LIPG, as associated with HDL concentrations, with some
of these SNPs also reported to have pleiotropic effects
on LDL cholesterol and triglyceride concentrations. All
SNPs were primarily selected for their impact on HDL.
Weighted and unweighted GRS were derived from this
additional set of 15 SNPs (Score 2; 2a = unweighted, 2b =
weighted). SNPs (n = 26) from both sets were also
combined to derive unweighted and weighted combined
GRS; two pairs of SNPs (rs2338104 and rs7134594;
rs2271293 and rs16942887) are in strong linkage disequi-
librium (r2 > 0.90), and as such two SNPs (rs7134594 and
rs2271293) were excluded from the combined scores.
SNPs in the combined GRS were weighted by their effect
sizes in mmol/L. The effect sizes used were drawn from
the Voight et al. paper or the Global Lipid Genetic Con-
sortium GWAS for Lipids paper that Voight et al. cited
[4,18]. All derived GRS (1a, 1b, 2a, 2b, Combined
Unweighted, Combined Weighted) were tested for associ-
ation with HDL, LDL and triglycerides to evaluate
whether the GRS were a measure of genetic contributions
to either HDL only or to global lipid levels.
For all GRS, the effect allele was assigned as the allele
associated with an increase in plasma HDL concentra-
tions, i.e., an increase in GRS can be interpreted as an
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HDL, as seen in the GRS used by Voight et al. [4].
Unweighted scores were derived by adding the number
of effect alleles across each SNP. The SNPs were also
weighted by their previously reported effect sizes [4]. For
the weighted scores, the number of effect alleles pos-
sessed by an individual at a particular SNP locus was
multiplied by a weight derived from that SNP’s effect
size contribution to the total effect size for all SNPs in-
cluded in the GRS. For individuals missing genotype
data for a particular SNP, the mean genotype calculated
in the DHS for that given SNP was assigned [19].Statistical analysis
For statistical analyses, continuous variables were trans-
formed as necessary to approximate normality. Single SNP
association analyses were performed using variance com-
ponents methods implemented in Sequential Oligogenic
Linkage Analysis Routines (SOLAR) version 6.4.1 (Texas
Biomedical Research Institute, San Antonio, TX) to ac-
count for relatedness between subjects [20]. Association
was examined assuming an additive model of inheritance.
Age and sex were included as covariates in single SNP as-
sociation analyses for HDL.
GRS were considered as both ordinal (three tertiles:
T1, T2, T3 derived from increasing tertile ranges) and
continuous variables. Relationships between the GRS and
HDL, LDL, triglycerides, CAC, and prior history of CVD
and MI were examined using marginal models with
generalized estimating equations. The models account for
familial correlation using a sandwich estimator of the vari-
ance under exchangeable correlation. Relationships be-
tween GRS and both all-cause and CVD-mortality were
examined using Cox proportional hazards models with
sandwich-based variance estimation due to the inclusion
of related individuals in this study. Associations were ad-
justed for covariates including age, sex, BMI, smoking sta-
tus (history of current or prior smoking), hypertension,
cholesterol medication use, prior CVD, oral T2D medica-
tion use, and insulin use as indicated. All analyses were
performed in SAS 9.3 (SAS Institute, Cary, NC). Statistical
significance was accepted at p < 0.05.Results
The goal of this study was to assess the impact of HDL-
associated SNPs on CVD risk in subjects from the DHS
of families enriched for T2D. We assessed the relation-
ships between GRS based on HDL-associated SNPs and
both subclinical CVD and mortality risk. The clinical
characteristics of the 983 European American individuals
withT2D included in the study are summarized in Table 1.
Subjects exhibited a variety of known CVD risk factors,
including hypertension, high body mass, and dyslipidemia.Subclinical CVD was prevalent, demonstrated by the large
number of subjects who had detectable CAC.
A total of 28 SNPs were genotyped (Table 2), including
13 SNPs solely associated with HDL and 15 SNPs associ-
ated with HDL that may also have pleiotropic effects on
other lipid parameters [4]. We first performed single
SNP association analyses for these 28 SNPs included in
our GRS. Four SNPs (rs3764261, rs1800588, rs3890182,
rs4759375) were associated (7.00 × 10-5 < p < 0.02) with
HDL concentrations, with the estimated effects in the
same direction and of similar magnitude as those previ-
ously reported by Voight et al. [4]. The coding variant in
LIPG (rs61755018) reported by Voight et al. was not
significantly associated with HDL concentrations in our
cohort [4].
Next, weighted and unweighted GRS were analyzed.
One GRS was derived from 13 SNPs (rs386000 excluded)
reported to have effects solely on HDL (Score 1; 1a =
unweighted, 1b = weighted; Table 2); scores ranged from
8.0 to 21.0 (14.7 ± 2.2, mean ± SD) for GRS 1a and from
7.8 to 21.0 (13.4 ± 2.1) for GRS 1b. The second GRS was
derived from an additional set of 15 SNPs associated with
HDL concentrations, some of which also have pleiotropic
effects on LDL cholesterol and triglycerides (Score 2; 2a =
unweighted, 2b = weighted; Table 2); scores ranged from
7.0 to 20.0 (13.3 ± 2.0) for GRS 2a and from 5.4 to 17.8
(11.0 ± 2.1) for GRS 2b. Additional GRS were constructed
from a combined set of 26 SNPs, with two SNPs not
included in the combined scores due to strong linkage
disequilibrium with other included SNPs (Combined
Unweighted and Combined Weighted scores; Table 2);
scores ranged from 17.0 to 36.0 (26.8 ± 2.9) for the Com-
bined Unweighted GRS and from 12.2 to 31.8 (21.2 ± 3.2)
for the Combined Weighted GRS.
An initial analysis of tertiles of GRS 1 and 2 (i.e. upper,
middle, and lower third of GRS distribution) as an or-
dinal variable was performed to test for a linear trend of
association with plasma HDL concentrations. As GRS 1
and 2 were linearly associated with HDL concentrations
(6.18 × 10-6 < p < 0.007 in models adjusted for additional
CVD risk factors), we next examined the GRS as con-
tinuous variables, including GRS 1 and 2 and the Com-
bined GRS. When analyses were adjusted for age, sex,
and BMI, all weighted and unweighted GRS were associ-
ated with increased HDL (Table 3) but were not associ-
ated with LDL cholesterol or triglyceride concentrations
(p > 0.05). In addition, significant associations were ob-
served between several of the GRS and CAC (Table 3).
This suggests a potential impact of a genetic predispos-
ition to increased HDL on reduced risk for subclinical
CVD in patients with T2D. Further analyses indicated
that the GRS were not significantly associated with
CVD-mortality (Table 4), nor were any significant asso-
ciations observed between the GRS and history of prior
Table 1 Demographic and clinical characteristics of 983
individuals with type 2 diabetes from the Diabetes Heart
Study
Mean ± SD or % Median (range)
Demographic information
Age (years) 62.5 ± 9.1 63 (34.2-86)
Gender (% female) 51.8%
T2D Duration (years) 10.5 ± 7.2 8 (0-46)
Smoking (current or past) (%) 59.4%




Deceased (from CVD) (%) 10.3%
Body composition
Height (cm) 168.7 ± 9.7 168.5 (122.8-202.0)
Weight (kg) 92.2 ± 20.3 89.5 (40.8-209.2)
BMI (kg/m2) 32.3 ± 6.6 31.2 (17.1-58.0)
Medications
Cholesterol Medications (%) 47.8%
Oral T2D Medications (%) 78.8%
Insulin (%) 27.6%
Blood pressure
Systolic BP (mmHg) 140 ± 18.9 138.5 (94-260)
Diastolic BP (mmHg) 72.7 ± 10.3 72 (36.5-106)
Hypertension (%) 88.9%
Blood biochemistry
Glucose (mg/dL) 148.1 ± 56.2 135 (16-463)
Hemoglobin A1C (%) 7.6 ± 1.7 7.2 (4.3-18.3)
Total Cholesterol (mg/dL) 184.9 ± 43.7 180.5 (65-427)
HDL cholesterol (mg/dL) 42.2 ± 12 41 (8-98)
LDL cholesterol (mg/dL) 102.8 ± 32.6 100 (12-236)




1888 ± 3382 478 (0-50415)
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were also not associated with all-cause mortality, with
the exception of the nominal associations of GRS 2b,
the weighted GRS which includes some SNPs with
pleiotropic effects on lipid parameters other than HDL,
and the Combined Weighted GRS (Table 4). Analyses
were also performed with further adjustment for dia-
betic medication use; results were essentially unchanged
(Additional files 1 and 2).
In an effort to further quantify these findings, tertiles
of GRS 1 and 2 were also analyzed in reference to the
lowest GRS tertile. The highest tertile was consistently as-
sociated with increased HDL concentrations (Additionalfile 3), with GRS 2b displaying the strongest association
(p = 4.31 × 10-5 for comparison of the highest in reference
to the lowest GRS tertile). Further quantification of risk
for all-cause mortality suggests individuals in the highest
tertile for GRS 2b experience an approximate 40% reduc-
tion in risk of mortality compared to those in the lowest
tertile (HR: 0.57; 95% CI: 0.39- 0.83; p = 0.003).
Discussion
The present study evaluated HDL-associated SNPs in
patients with T2D using weighted and unweighted GRS.
It is important to assess the impact of HDL-associated
SNPs in patients with T2D, as decreased HDL concentra-
tions are epidemiologically associated with higher CVD-
mortality and are often observed in patients with T2D
[2,3]. In addition to conventional lipid parameters, mea-
sures of prevalent disease, and mortality, we evaluated as-
sociations of these GRS with CAC. CAC has been shown
in the DHS and other cohorts to be a strong independent
predictor of CVD events and mortality [6,8]. Compared to
individuals with low or nonexistent CAC (CAC 0–9),
individuals in the DHS with very high CAC (≥ 1,000) ex-
perienced >6-fold increased risk for all-cause mortality
and >11-fold increased risk for CVD-mortality [8,21].
CAC has not previously been examined in studies of the
impact of HDL-associated variants on CVD risk. Hence,
analysis of our HDL GRS with this subclinical measure of
CVD was unique and of clinical relevance.
For the weighted and unweighted GRS assessed, higher
GRS values were clearly associated with increased plasma
HDL. The GRS were not associated with LDL cholesterol
and triglyceride concentrations, allowing assessment of the
effects of genetic predisposition to higher or lower HDL
without confounding effects from associations with other
lipid parameters. No evidence of association between the
GRS and CVD-mortality was observed; however, associa-
tions between the GRS and CAC were observed. These
associations point to a potential reduction in risk for sub-
clinical CVD in patients with T2D with a genetic predis-
position to increased HDL.
Prior analyses of HDL-associated SNPs
Recently, Voight et al. [4] evaluated two sets of SNPs as-
sociated with higher HDL to determine whether HDL-
associated SNPs would confer protection from MI in the
general population. They concluded that a genetic pre-
disposition to higher HDL did not detectably influence
MI risk. However, Voight et al. did not address the asso-
ciation of their GRS in high CVD risk groups such as
patients with T2D [4]. Moreover, it is important to test
the applicability of results from extremely large meta-
analyses in community-based cohorts. This is a necessary
step in assessing the value of these GRS for introduction
into clinical medicine. We hypothesized that GRS of
Table 2 HDL-associated SNPs included in the genetic risk scores (GRS)
SNPs in risk scores 1a and 1b
SNP Chr Position Gene(s) Source Alleles
(Major/Minor)




rs1689800 1 182168885 GLUL, ZNF648 Exome Chip A/G A 0.628 0.01
rs13107325 4 103188709 SLC39A8 Exome Chip C/T C 0.925 0.02
rs2293889 8 116599199 TRPS1 Sequenom G/T G 0.554 0.01
rs2923084 11 10388782 AMPD3 Exome Chip A/G A 0.815 0.01
rs7134594 12 110000193 MMAB Exome Chip T/C T 0.520 0.01
rs4759375 12 123796238 SBNO1 Imputed data C/T T 0.092 0.02
rs838880 12 125261593 SCARB1 Exome Chip T/C C 0.337 0.02
rs16942887 16 67928042 PSKH1 Exome Chip G/A A 0.115 0.03
rs881844 17 37810218 STARD3 Imputed data G/C G 0.652 0.01
rs4082919 17 76377482 PGS1 Sequenom G/T T 0.483 0.01
rs7255436 19 8433196 ANGPTL4 Exome Chip A/C A 0.506 0.01
rs737337 19 11347493 DOCK6 Exome Chip T/C T 0.900 0.02
rs181362 22 21932068 UBE2L3 Sequenom C/T C 0.813 0.01
SNPs in risk scores 2a and 2b
rs4846914 1 230295691 GALNT2 Sequenom A/G A 0.606 0.02
rs17145738 7 72982874 TBL2, BCL7B Exome Chip C/T T 0.124 0.03
rs17482753 8 19832646 LPL Exome Chip G/T T 0.095 0.08
rs17321515 8 126486409 TRIB1 GWAS A/G G 0.465 0.02
rs471364 9 15289578 TTC39B Exome Chip T/C T 0.896 0.03
rs3890182 9 107647655 ABCA1 Exome Chip G/A G 0.890 0.03
rs174547 11 61570783 FADS1 Exome Chip T/C T 0.668 0.03
rs6589566 11 116652423 ZNF259, APOA5 GWAS A/G A 0.924 0.05
rs2338104 12 109895168 KCTD10 Exome Chip G/C G 0.520 0.03
rs1800588 15 58723675 LIPC Exome Chip C/T T 0.207 0.05
rs3764261 16 56993324 CETP Exome Chip C/A A 0.331 0.1
rs2271293 16 67902070 NUTF2 Exome Chip G/A A 0.113 0.03
rs61755018 18 47109955 LIPG Imputed data A/G G 0.007 0.14
rs2967605 19 8469738 RAB11B Exome Chip C/T C 0.812 0.05
rs16988929 20 42904315 GDAP1L1 Imputed data C/T T 0.002 0.01
SNPs in Risk Score 1a (unweighted) and Risk Score 1b (weighted) have effects on HDL levels only, while SNPs in Risk Score 2a (unweighted) and Risk Score 2b
(weighted) have effects on HDL levels as well as some pleiotropic effects on LDL and triglyceride levels. Allele frequencies in the DHS are provided along with the
effect size estimates (β value) reported by Voight et al.
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the effect of HDL concentrations on CVD risk in patients
with T2D.
Prior studies in the general population have generally
shown little impact of genetic variants affecting HDL
concentrations on CVD risk. In two large Danish stud-
ies, variants associated with a decrease in HDL choles-
terol did not increase CVD risk [22,23]. In another study
with 8,473 Caucasian participants, GRS were strongly as-
sociated with HDL concentrations, but were not associ-
ated with CVD [24]. However, few previous studies have
focused on patients with T2D, so it is unclear whetherHDL-associated SNPs impact CVD risk in this group, a
gap that we addressed in this study.
Analysis of GRS for associations with lipid parameters
We did not detect many of the single SNP associations
with HDL concentrations reported by Voight et al. [4].
This is not surprising, as the current study has lower
power to detect associations given the modest effect
sizes previously reported. However, we observed signifi-
cant associations between all of the GRS assessed and
HDL, allowing us to consider the impact of genetic de-
terminants of HDL concentrations on CVD risk. Some
Table 3 Associations between HDL genetic risk scores and HDL, LDL, triglycerides, and coronary artery calcified plaque
(CAC)
Model 1 Model 2 Model 3
β Estimate (CI) p-value β Estimate (CI) p-value β Estimate (CI) p-value
HDL
Risk score 1a 0.027 (-0.001- 0.055) 0.057 0.030 (0.005- 0.056) 0.022 0.033 (0.007- 0.058) 0.013
Risk score 1b 0.033 (0.003- 0.063) 0.031 0.034 (0.006- 0.061) 0.018 0.035 (0.008- 0.063) 0.012
Risk score 2a 0.046 (0.016- 0.076) 0.003 0.051 (0.023- 0.079) 3.85 × 10-4 0.052 (0.024- 0.080) 3.06 × 10-4
Risk score 2b 0.061 (0.034- 0.089) 1.42 × 10-5 0.062 (0.036- 0.088) 2.60 × 10-6 0.063 (0.037- 0.088) 1.44 × 10-6
Combined unweighted 0.035 (0.015- 0.055) 0.001 0.039 (0.021- 0.058) 3.63 × 10-5 0.040 (0.021- 0.058) 2.34 × 10-5
Combined weighted 0.043 (0.025- 0.061) 4.65 × 10-6 0.044 (0.027- 0.061) 4.90 × 10-7 0.044 (0.027- 0.061) 2.75 × 10-7
LDL
Risk score 1a 0.317 (-0.678- 1.311) 0.532 0.260 (-0.74- 1.260) 0.611 0.245 (-0.759- 1.248) 0.633
Risk score 1b 0.243 (-0.782- 1.268) 0.642 0.177 (-0.854- 1.207) 0.737 0.140 (-0.887- 1.167) 0.789
Risk score 2a −0.823 (-1.978- 0.332) 0.163 −0.838 (-1.987- 0.312) 0.153 −0.805 (-1.955- 0.346) 0.170
Risk score 2b −0.507 (-1.614- 0.600) 0.369 −0.604 (-1.713- 0.506) 0.286 −0.585 (-1.698- 0.529) 0.303
Combined unweighted −0.243 (-1.018- 0.533) 0.539 −0.261 (-1.033- 0.512) 0.509 −0.266 (-1.038- 0.507) 0.501
Combined weighted −0.260 (-0.988- 0.468) 0.484 −0.325 (-1.054- 0.404) 0.383 −0.327 (-1.060- 0.406) 0.381
Triglycerides
Risk score 1a −0.002 (-0.019- 0.015) 0.853 −0.005 (-0.021- 0.012) 0.591 −0.006 (-0.022- 0.010) 0.469
Risk score 1b −0.005 (-0.022- 0.013) 0.595 −0.007 (-0.024- 0.010) 0.402 −0.008 (-0.024- 0.009) 0.374
Risk score 2a −0.013 (-0.034- 0.008) 0.220 −0.016 (-0.036- 0.004) 0.123 −0.015 (-0.036- 0.005) 0.133
Risk score 2b −0.009 (-0.028- 0.010) 0.370 −0.013 (-0.031- 0.005) 0.162 −0.013 (-0.031- 0.005) 0.163
Combined unweighted −0.010 (-0.023- 0.004) 0.157 −0.012 (-0.025- 0.001) 0.076 −0.012 (-0.025- 0.001) 0.072
Combined weighted −0.007 (-0.020- 0.005) 0.246 −0.010 (-0.022- 0.002) 0.092 −0.010 (-0.022- 0.002) 0.096
Coronary Artery Calcified Plaque (CAC)
Risk score 1a −0.079 (-0.154- -0.003) 0.042 −0.065 (-0.128- -0.001) 0.046 −0.068 (-0.128- -0.008) 0.027
Risk score 1b −0.067 (-0.146- 0.012) 0.097 −0.053 (-0.119- 0.014) 0.119 −0.059 (-0.123- 0.004) 0.065
Risk score 2a −0.072 (-0.154- 0.011) 0.089 −0.063 (-0.134- 0.009) 0.085 −0.082 (-0.149- -0.014) 0.017
Risk score 2b −0.117 (-0.197- -0.036) 0.005 −0.088 (-0.156- -0.020) 0.011 −0.101 (-0.163- -0.038) 0.002
Combined unweighted −0.083 (-0.140- -0.026) 0.004 −0.077 (-0.123- -0.031) 0.001 −0.080 (-0.124- -0.037) 3.18 × 10-4
Combined weighted −0.087 (-0.141- -0.033) 0.002 −0.069 (-0.114- -0.024) 0.002 −0.075 (-0.117- -0.034) 3.85 × 10-4
Analysis was performed using marginal models with generalized estimating equations. Model 1 is unadjusted; Model 2 is adjusted for age, sex, and body mass
index (BMI); Model 3 is adjusted for age, sex, BMI, smoking, hypertension, and prior cardiovascular disease. Associations are reported as the β estimate and its
95% confidence interval (CI).
Raffield et al. Cardiovascular Diabetology 2013, 12:95 Page 7 of 10
http://www.cardiab.com/content/12/1/95past studies of SNPs associated with HDL in patients
with T2D have examined SNPs with pleiotropic effects
on other lipid parameters or other traits, such as obesity,
which could also influence CVD risk [25-28]. An im-
portant strength of this study is that the GRS were not
associated with LDL cholesterol and triglyceride concen-
trations, indicating the GRS are mainly informative for
an individual’s HDL concentration, as opposed to more
global lipid concentrations.
In our study, consistent with the GRS used by Voight
et al., a higher GRS indicates a predisposition to higher
HDL [4]. While we refer to all GRS as risk scores by con-
vention, epidemiological data would in fact indicate that
higher GRS values should be associated with increasedprotection from CVD, not increased risk, as higher plasma
HDL is protective [3]. However, constructing the GRS so
that higher GRS values would be associated with decreased
HDL would not have changed our results; p-values would
remain unchanged and effect estimates would be of the
same magnitude in the opposite direction.
Analysis of GRS for associations with mortality and
subclinical CVD
Association of the GRS with HDL allowed us to subse-
quently consider the impact of genetic predisposition to
higher or lower HDL on all-cause mortality and CVD-
mortality in T2D. While the HDL GRS were not associated
with CVD-mortality, association with all-cause mortality
Table 4 Association between HDL genetic risk scores analyzed as a continuous variable and all-cause and CVD-
mortality
Model 1 Model 2 Model 3
All-cause mortality HR (CI) p-value HR (CI) p-value HR (CI) p-value
Risk score 1a 0.96 (0.91, 1.02) 0.208 0.98 (0.92, 1.03) 0.373 0.97 (0.92, 1.03) 0.295
Risk score 1b 0.96 (0.91, 1.02) 0.175 0.97 (0.92, 1.03) 0.314 0.97 (0.92, 1.02) 0.228
Risk score 2a 0.96 (0.90, 1.03) 0.235 0.97 (0.91, 1.03) 0.302 0.96 (0.90, 1.03) 0.232
Risk score 2b 0.92 (0.87, 0.98) 0.010 0.93 (0.88, 0.99) 0.020 0.93 (0.88, 0.98) 0.011
Combined unweighted 0.96 (0.92- 1.01) 0.115 0.97 (0.93- 1.01) 0.170 0.97 (0.93- 1.01) 0.162
Combined weighted 0.95 (0.91- 0.99) 0.009 0.96 (0.92- 0.99) 0.017 0.95 (0.92- 0.99) 0.011
CVD mortality
Risk score 1a 1.00 (0.92, 1.09) 0.958 1.01 (0.93, 1.10) 0.771 1.00 (0.92, 1.09) 0.988
Risk score 1b 1.00 (0.92, 1.09) 0.936 1.01 (0.93, 1.10) 0.880 0.99 (0.91, 1.08) 0.835
Risk score 2a 1.03 (0.93, 1.13) 0.621 1.03 (0.94, 1.13) 0.542 1.02 (0.94, 1.12) 0.622
Risk score 2b 0.96 (0.89, 1.05) 0.407 0.98 (0.90, 1.06) 0.547 0.97 (0.90, 1.05) 0.477
Combined unweighted 1.00 (0.94- 1.07) 0.955 1.01 (0.95- 1.07) 0.826 1.00 (0.94- 1.07) 0.890
Combined weighted 0.98 (0.92- 1.04) 0.429 0.98 (0.93- 1.04) 0.573 0.98 (0.93- 1.04) 0.502
Analysis was performed using Cox proportional hazards regression. Model 1 is unadjusted; Model 2 is adjusted for age and sex; Model 3 is adjusted for age, sex,
body mass index, smoking, hypertension, cholesterol medication use, and prior cardiovascular disease. The hazard ratio (HR) and its 95% confidence interval (CI)
are reported.
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cludes SNPs with pleiotropic effects on LDL cholesterol
and triglycerides, and the Combined Weighted GRS. It is
possible that these associations are due to the reported
pleiotropic effects on LDL and triglycerides of some of the
included SNPs, although the GRS overall were not associ-
ated with LDL and triglyceride concentrations. Alterna-
tively this observation may be due to impacts of HDL on
risk for mortality through pathways other than CVD. A
recent study by Qi et al. [29] examined HDL, LDL, and
triglyceride GRS and demonstrated a modest increase in
T2D risk with increased HDL GRS. While the current
study consists entirely of T2D affected individuals, the
study by Qi et al. [29] suggests a role for HDL in diabetes
pathogenesis, perhaps impacting mortality. Apart from re-
verse cholesterol transport, the cardinal function of HDL
in ameliorating CVD risk, HDL particles also demonstrate
anti-inflammatory, antioxidant, and anti-apoptotic effects
which may be important mechanisms contributing to risk
for mortality [30]. Further, while the GRS assessed in this
study are associated with HDL concentrations, their impact
on HDL particle composition and function is unclear and
may further contribute to mechanisms underpinning the
observed associations with all-cause mortality.
While we did not observed significant associations be-
tween the HDL GRS and CVD-mortality, we did observe
interesting associations between the GRS and CAC, a
measure of subclinical CVD risk. We observed an associ-
ation between GRS 1a, the unweighted GRS which con-
tains SNPs which affect HDL concentrations only, and
CAC. Likewise associations with CAC were observed forGRS 2a and 2b (SNPs with pleiotropic effects on lipid
parameters other than HDL), as well as the Combined
Unweighted and Weighted GRS. This points to a potential
role of HDL-associated SNPs in subclinical CVD risk; it is
possible we are not observing the impact of HDL-
associated SNPs on CVD-mortality due to a low number
of events, with association with CAC observed due to in-
creased power for analyses of this continuous trait. This
may point to a differing impact of HDL-associated SNPs
in individuals with T2D than is seen in most studies of the
general population. However, little work on associations
between CAC and HDL-associated SNPs has been done
in the general population, so these SNPs may be associ-
ated with CAC in the general population as well.
Limitations
SNPs included in our GRS were selected for the strength
of their association with HDL concentrations in previous
studies [4,18]; other SNPs more modestly associated
with HDL were not the focus of the current study but
may, in some cases, have a greater impact on disease risk
[27,31]. The impact of genetic variants associated with
HDL may also be modulated by environmental factors,
which was not assessed here [32,33]. The disparate treat-
ments prescribed to individuals in the DHS, including
oral T2D medications and insulin, may also impact
CVD outcomes; however, inclusion of these covariates
in our models did not substantially change our results
(Additional files 1 and 2). For analyses of CVD mortal-
ity, our power to detect a modest effect (HR ~ 1.1) associ-
ated with our GRS was limited (<60% power); however,
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http://www.cardiab.com/content/12/1/95our power to detect a larger effect (HR ~ 1.2) was high
(>95% power). As a result, we cannot exclude a modest
impact of our HDL GRS on CVD mortality that was not
detected in this study. In contrast, limited power was
not a concern for analyses of all-cause mortality (>85%
power to detect a HR of ~1.1) due to the increased
number of events, nor for analyses of continuous mea-
sures such as CAC and HDL (>85% power for a modest
effect size of 0.02).
Conclusions
In summary, the GRS analyzed in this paper provide a
useful tool for assessing the impact of genetic predispos-
ition to higher or lower HDL concentrations on risk for
CVD in patients with T2D. As has been observed in
studies in the general population, there was no associ-
ation between the HDL GRS and risk of CVD-mortality.
However, associations between some of the GRS and
CAC were observed, pointing to a potential role of gen-
etic variants affecting HDL concentrations in risk for
subclinical CVD in patients with T2D. Further study of
HDL-associated genetic variants will be needed to fur-
ther clarify whether these variants are important deter-
minants of CVD risk in T2D affected individuals.
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Additional file 1: Associations between HDL genetic risk scores and
HDL, LDL, triglycerides, and coronary artery calcified plaque (CAC),
with and without adjustment for diabetic medication use.
Additional file 2: Association between HDL genetic risk scores
analyzed as a continuous variable and all-cause and CVD-mortality,
with and without adjustment for diabetic medication use.
Additional file 3: Association between HDL genetic risk score
tertiles and all-cause and CVD- mortality using unadjusted
proportional hazards regression models and between risk scores
and HDL levels using unadjusted marginal models incorporating
generalized estimating equations. Hazard ratios (HR) or β estimates
(as appropriate) and 95% confidence intervals (CI) are reported
relative to the lowest tertile.
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